You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博安生物(06955.HK)與健康元簽訂獨家授權協議

格隆匯1月26日丨博安生物(06955.HK)公吿,公司已與健康元藥業集團股份有限公司簽訂協議。該協議內容有關公司在研產品BA2101注射液在哮喘和慢性阻塞性肺疾病(COPD)及其他呼吸道疾病治療領域的適應症的獨家授權開發及商業化。

根據該協議,公司將授予健康元該產品的獨家權利,以於中國大陸進行該產品於該領域內適應症的獨家開發、註冊、生產和商業化。公司則繼續持有該產品於協議區域在該領域以外所有其他適應症的相關權利,以及該產品在協議區域以外全部適應症的全部權利。作為獨家許可的代價,健康元將在簽署協議後向公司支付首付款及開發里程碑付款。健康元亦同意根據該產品於協議地區達成的淨銷售額向公司支付潛在銷售里程碑付款和銷售提成。該等付款均不可退還。此外,健康元負責該產品在協議區域的該領域所有適應症臨牀及以後的開發活動並承擔相關費用。

BA2101注射液由公司自主研發,為創新的長效全人源單克隆IgG4型抗體,靶向白細胞介素-4受體亞基α(IL-4Rα),可同時抑制IL-4及IL-13信號通路,調節Th2型炎症,降低嗜酸性粒細胞含量及IgE水平。該產品擬用於治療Th2型炎症引起的過敏性疾病。目前,公司已獲得特應性皮炎、哮喘、COPD、慢性鼻竇炎伴鼻息肉、結節性癢疹、慢性自發性蕁麻疹適應症的臨牀試驗批准。

此次的合作方健康元是呼吸治療領域的中國領軍企業,圍繞呼吸用藥佈局重點品種並形成豐富的產品組合,並在全國範圍內擁有呼吸專線營銷團隊,在該治療領域處於領先地位。通過此次合作,公司與健康元將積極發揮各自在研發及商業化方面的優勢,加快推進BA2101注射液在哮喘和COPD等疾病中的臨牀開發進程;此外,公司也將憑藉高效的臨牀開發和推進能力,加速更多適應症的開發,使患者及早獲益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account